ReviewCurrent neuropharmacology2018
Potential Therapeutics for Vascular Cognitive Impairment and Dementia.
Review in Current neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Effects of acupuncture on cognitive function and lipid metabolism in post-stroke vascular dementia: a systematic review and meta-analysis of randomized controlled trials.Frontiers in aging neuroscience · 2026Pooled it
- Efficacy of acupuncture in animal models of vascular dementia: A systematic review and network meta-analysis.Frontiers in aging neuroscience · 2022Pooled it
- Pooled it
- Improvement of poststroke cognitive impairment by intermittent theta bursts: A double-blind randomized controlled trial.Brain and behavior · 2022Trial
- Exploring synaptic density patterns in cerebral small vessel disease: insights from [European journal of nuclear medicine and molecular imaging · 2026Article
- The nitrate-nitrite-nitric oxide pathway of neuroinflammation and cognitive impairment in ischemic stroke.Frontiers in immunology · 2026Review
- Electroacupuncture alleviates cognitive impairment in mice with vascular dementia by regulating the cholinergic vasodilation system.Frontiers in aging neuroscience · 2026Article
- High-fat feeding has sex-dependent effects on the structure and biomechanical properties of cerebral parenchymal arterioles and cognitive function.American journal of physiology. Heart and circulatory physiology · 2025Article
- Korean medicine registry for cognitive disorder: A protocol for prospective observational multi-center study.PloS one · 2025Article
- Nitric Oxide Metabolite Improves Cognitive Impairment by Reducing the Loss of Parvalbumin Inhibitory Interneurons in a Novel Mouse Model of Vascular Dementia.Current neuropharmacology · 2025Article
- Role of miRNAs in neurovascular injury and repair.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Review
- Elevated protease-activated receptor 4 (PAR4) gene expression in Alzheimer's disease predicts cognitive decline.Neurobiology of aging · 2024Article
- Study of electronic biofeedback combined with nursing intervention in the treatment of vascular cognitive impairment-no dementia.Acta neurologica Belgica · 2024Article
- The Roles of RhoA/ROCK/NF-κB Pathway in Microglia Polarization Following Ischemic Stroke.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2024Review
- Parkinson's Disease Dementia Patients: Expression of Glia Maturation Factor in the Brain.International journal of molecular sciences · 2024Article
- A review of SaiLuoTong (MLC-SLT) development in vascular cognitive impairment and dementia.Frontiers in pharmacology · 2024Review
- Efficacy of repetitive transcranial magnetic stimulation with different application parameters for post-stroke cognitive impairment: a systematic review.Frontiers in neuroscience · 2024Review
- Effects of Dl-3-n-butylphthalide on cognitive functions and blood-brain barrier in chronic cerebral hypoperfusion rats.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Article
- Modeling Gasotransmitter Availability to Brain Capillary Endothelial Cells with Ultrasound-sensitive Microbubbles.Pharmaceutical research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs the human lifespan increases, the number of people affected by agerelated dementia is growing at an epidemic pace. Vascular pathology dramatically affects cognitive profiles, resulting in dementia and cognitive impairment. While vascular dementia itself constitutes a medical challenge, hypo-perfusion/vascular risk factors enhance amyloid toxicity and other memory- damaging factors and hasten Alzheimer's disease (AD) and other memory disorders' progression, as well as negatively affect treatment outcome.
methodsResearch and online content related to vascular cognitive impairment and dementia is reviewed, specifically focusing on the potential treatment of the disorder.
resultsFew therapeutic options are currently available to improve the prognosis of patients with vascular dementia and cognitive impairment, mixed AD dementia with vascular pathology, or other memory disorders. Emerging evidence, however, indicates that, like AD and other memory disorders, synaptic impairment underlies much of the memory impairment in the cognitive decline of vascular cognitive impairment and vascular dementia.
conclusionEffective rescues of the memory functions might be achieved through synaptic and memory therapeutics, targeting distinct molecular signaling pathways that support the formation of new synapses and maintaining their connections. Potential therapeutic agents include: 1) memory therapeutic agents that rescue synaptic and memory functions after the brain insults; 2) antipathologic therapeutics and an effective management of vascular risk factors; and 3) preventative therapeutic agents that achieve memory therapy through functional enhancement. These therapeutic agents are also likely to benefit patients with AD and/or other types of memory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.